Health Catalyst (NASDAQ:HCAT) CEO Daniel D. Burton sold 24,439 shares of Health Catalyst stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $30.25, for a total value of $739,279.75. Following the transaction, the chief executive officer now directly owns 262,162 shares in the company, valued at approximately $7,930,400.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ HCAT opened at $27.60 on Wednesday. The stock has a market capitalization of $1.09 billion and a price-to-earnings ratio of -5.23. The business’s 50 day moving average is $28.89 and its two-hundred day moving average is $29.64. Health Catalyst has a 12-month low of $17.48 and a 12-month high of $49.85. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 0.24.
Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. The firm had revenue of $45.12 million for the quarter, compared to the consensus estimate of $44.12 million. Health Catalyst had a positive return on equity of 30.42% and a negative net margin of 38.74%. Health Catalyst’s revenue for the quarter was up 28.1% on a year-over-year basis. Equities analysts forecast that Health Catalyst will post -1.6 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of HCAT. Valeo Financial Advisors LLC lifted its position in shares of Health Catalyst by 220.7% during the 1st quarter. Valeo Financial Advisors LLC now owns 991 shares of the company’s stock valued at $25,000 after acquiring an additional 682 shares during the period. Altshuler Shaham Ltd purchased a new position in Health Catalyst in the 4th quarter valued at approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Health Catalyst in the 1st quarter valued at approximately $37,000. Ameritas Investment Partners Inc. raised its holdings in Health Catalyst by 143.0% during the first quarter. Ameritas Investment Partners Inc. now owns 1,640 shares of the company’s stock worth $43,000 after purchasing an additional 965 shares during the last quarter. Finally, Citigroup Inc. boosted its position in Health Catalyst by 438.8% during the fourth quarter. Citigroup Inc. now owns 2,015 shares of the company’s stock worth $70,000 after purchasing an additional 1,641 shares in the last quarter. 71.23% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded Health Catalyst from a “buy” rating to a “hold” rating in a report on Tuesday, May 19th. Raymond James lowered their price objective on shares of Health Catalyst from $46.00 to $40.00 and set a “strong-buy” rating on the stock in a research report on Wednesday, May 13th. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. SVB Leerink increased their target price on shares of Health Catalyst from $31.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Finally, Stifel Nicolaus assumed coverage on Health Catalyst in a report on Thursday, June 18th. They set a “buy” rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Health Catalyst currently has an average rating of “Buy” and a consensus price target of $40.00.
About Health Catalyst
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services.
Featured Story: Is a Roth IRA right for you?
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.